Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/8XvMsGtul2 https://t.co/HG0QOu5V77

FDA Warning on CAR-T Cell Therapy The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies. https://t.co/uxY7xgqgqn https://t.co/xyZrXXGGIy

Korean ULTRA registry studied 117 Gout pts starting ULT; compared T2T achievers (SUA< 6) vs non-achievers. @6 mos, 71% reached target SUA (w/ better adherence (98% vs. 76%) than non-achievers. T2T achievers assoc w/ good adherence, +FamHx, & HTN meds https://t.co/wTuvPqcan5 https://t.co/QD9j923sSa

Metanalysis shows the prevalence of self-reported sleep problems in #PsA ranged 30% to 85%. 6 studies showed poor sleep quality in 73% (statistically higher than controls 27%). Sleep ranked in the top 4 health-related quality of life domains by PsA pts. https://t.co/d79Ji3KCBu https://t.co/HJpqUIQ8x6

FINAL DAY for early bird pricing for RheumNow Live. Take advantage of this discounted price TODAY! https://t.co/UW9SMjEBYB https://t.co/DX2SJZYkUW

Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/Hhxr7hscaL https://t.co/J46JvHwRmc

Clinical Practice Res Database studied 51K gout pts before ULT therapy, 36% had  ≥ 1 recurrent flares, 17% flared w/in 12 mos of Dx. Flares risk: Male, blacks, obese, CHF, CKD, CVD, diuretics, Hi SUA (HR 4.6). Only 28% Given ULT w/in 12 mos of Dx https://t.co/TAHBDxA6Th https://t.co/rwztpe7y2r

QD Clinic - Eosinophilia in RA High Eosinophil counts in Stable RA - what's the differential Dx?. https://t.co/au606vNQob https://t.co/VJneBfGr4P

ICYMI: Here at Last: Treatment Options for VEXAS We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to #ACR23 there has been relatively little to say about how to treat it. https://t.co/FnygxtDwx8 https://t.co/2j1nbsAAp0

ICYMI: Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups. https://t.co/wn5iDXibzi https://t.co/IVtKwdYDwN

Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/TRgtYCbnf2 https://t.co/7xgBU3apmy

EULAR 2023 Recommendations on Fatigue Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life. https://t.co/e2pP8bt9jg https://t.co/7R58j1oZKR